Algunas aprobaciones recientes de la Administración de Alimentos y Medicamentos (Food and Drug Administration, FDA) han hecho que las personas se enteren de que hay tratamientos agnósticos con respecto a los tumores. Pero, ¿qué significa eso y cómo podría beneficiar a alguien con cáncer? El director médico anterior (2013-2021) de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica), Richard L. Schilsky, aporta información sobre esta nueva forma de abordar el tratamiento del cáncer.

In this podcast, Cancer.Net Associate Editors discuss new research presented at the 2021 ASCO Annual Meeting in lung cancer, breast cancer, and sarcoma and describe what this research means for people with cancer.

Dr. Craig A. Portell discusses what CAR T-cell therapy is, how it works, what its common side effects are, and how it’s changing the landscape of how some types of cancers are treated.

The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.

Read early research highlights just released for the 2021 ASCO Annual Meeting. Topics include immunotherapy for melanoma and non-small cell lung cancer, PSA screening for prostate cancer, HPV vaccination, and Medicaid income eligibility limits.

Lea los puntos destacados de la investigación temprana que acaban de publicar para la reunión anual de la American Society of Clinical Oncology (Sociedad Americana de Oncología Clínica) de 2021. Los temas incluyen la inmunoterapia para el melanoma y el cáncer de pulmón de no microcítico (NSCLC, por sus siglas en inglés), la detección del antígeno prostático específico (PSA, por sus siglas en inglés) para el cáncer de próstata, la vacunación contra el VPH y los límites de elegibilidad de los ingresos de Medicaid.

Learn more about research presented at the 2021 Genitourinary Cancers Symposium, including immunotherapy for people with high-risk bladder cancer and a link between less PSA screening and diagnoses of metastatic prostate cancer.

ASCO’s 2021 Advance of the Year highlights how progress in the treatment of gastrointestinal (GI) cancers is driven by molecular testing of tumors.

Dr. Neeraj Agarwal discusses 3 clinical trials presented at the 2020 ESMO Virtual Congress that studied new treatments for advanced kidney cancer, prostate cancer, and bladder cancer.

Can immunotherapy be used to treat breast cancer? This expert Q&A explains.